AU2010328046C1 - Mice that make heavy chain antibodies - Google Patents

Mice that make heavy chain antibodies Download PDF

Info

Publication number
AU2010328046C1
AU2010328046C1 AU2010328046A AU2010328046A AU2010328046C1 AU 2010328046 C1 AU2010328046 C1 AU 2010328046C1 AU 2010328046 A AU2010328046 A AU 2010328046A AU 2010328046 A AU2010328046 A AU 2010328046A AU 2010328046 C1 AU2010328046 C1 AU 2010328046C1
Authority
AU
Australia
Prior art keywords
mouse
heavy chain
domain
human
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010328046A
Other languages
English (en)
Other versions
AU2010328046A1 (en
AU2010328046B2 (en
Inventor
Lynn Macdonald
Andrew J. Murphy
Sean Stevens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of AU2010328046A1 publication Critical patent/AU2010328046A1/en
Application granted granted Critical
Publication of AU2010328046B2 publication Critical patent/AU2010328046B2/en
Priority to AU2014233618A priority Critical patent/AU2014233618B2/en
Priority to AU2017261477A priority patent/AU2017261477C1/en
Publication of AU2010328046C1 publication Critical patent/AU2010328046C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2010328046A 2009-12-10 2010-12-10 Mice that make heavy chain antibodies Active AU2010328046C1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2014233618A AU2014233618B2 (en) 2009-12-10 2014-09-26 Mice that make heavy chain antibodies
AU2017261477A AU2017261477C1 (en) 2009-12-10 2017-11-14 Mice that make heavy chain antibodies

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28525009P 2009-12-10 2009-12-10
US61/285,250 2009-12-10
PCT/US2010/059845 WO2011072204A1 (en) 2009-12-10 2010-12-10 Mice that make heavy chain antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2014233618A Division AU2014233618B2 (en) 2009-12-10 2014-09-26 Mice that make heavy chain antibodies

Publications (3)

Publication Number Publication Date
AU2010328046A1 AU2010328046A1 (en) 2012-07-12
AU2010328046B2 AU2010328046B2 (en) 2014-07-31
AU2010328046C1 true AU2010328046C1 (en) 2018-01-18

Family

ID=43534479

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010328046A Active AU2010328046C1 (en) 2009-12-10 2010-12-10 Mice that make heavy chain antibodies

Country Status (24)

Country Link
US (9) US8754287B2 (enExample)
EP (3) EP2509409B1 (enExample)
JP (5) JP5909449B2 (enExample)
KR (2) KR101430514B1 (enExample)
CN (3) CN102711449B (enExample)
AU (1) AU2010328046C1 (enExample)
CA (1) CA2782936C (enExample)
CY (2) CY1118163T1 (enExample)
DK (2) DK2509409T3 (enExample)
ES (2) ES2595376T3 (enExample)
HR (1) HRP20190820T1 (enExample)
HU (2) HUE030208T2 (enExample)
IL (4) IL220150A0 (enExample)
LT (2) LT2509409T (enExample)
MY (2) MY173363A (enExample)
PL (2) PL2509409T3 (enExample)
PT (2) PT2509409T (enExample)
RS (1) RS58709B1 (enExample)
RU (1) RU2603102C2 (enExample)
SG (2) SG181477A1 (enExample)
SI (2) SI2954779T1 (enExample)
SM (1) SMT201900251T1 (enExample)
TR (1) TR201906488T4 (enExample)
WO (1) WO2011072204A1 (enExample)

Families Citing this family (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1776383B1 (en) 2004-07-22 2014-08-20 Erasmus University Medical Center Rotterdam Binding molecules
PL2346994T3 (pl) * 2008-09-30 2022-04-19 Ablexis, Llc Myszy knock-in do wytwarzania chimerycznych przeciwciał
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
DK3241435T3 (da) 2009-07-08 2021-08-23 Kymab Ltd Dyremodeller og terapeutiske molekyler
WO2011072204A1 (en) * 2009-12-10 2011-06-16 Regeneron Pharmaceuticals, Inc. Mice that make heavy chain antibodies
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
PL3248462T3 (pl) 2010-03-31 2024-07-08 Ablexis, Llc Modyfikacja myszy metodami inżynierii genetycznej w celu wytworzenia przeciwciał chimerycznych
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
CN103025884B (zh) 2010-07-26 2015-11-25 特里安尼公司 转基因动物和使用方法
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
EP2601298B1 (en) 2010-08-02 2016-11-30 Regeneron Pharmaceuticals, Inc. Mice that make binding proteins comprising vl domains
CN105861548B (zh) 2011-02-25 2020-01-10 瑞泽恩制药公司 Adam6小鼠
CN103619876A (zh) * 2011-03-10 2014-03-05 Hco抗体股份有限公司 双特异性三链抗体样分子
ES2872081T3 (es) 2011-08-05 2021-11-02 Regeneron Pharma Ratones con cadena ligera universal humanizada
GB2501753A (en) * 2012-05-04 2013-11-06 Kymab Ltd Human antibodies
AU2012311286B2 (en) * 2011-09-19 2018-07-26 Kymab Limited Antibodies, variable domains and chains tailored for human use
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
EP4074833A1 (en) 2011-10-17 2022-10-19 Regeneron Pharmaceuticals, Inc. Restricted immunoglobulin heavy chain mice
AU2012327223A1 (en) * 2011-11-30 2013-06-20 Wellstat Diagnostics, Llc. Assays, antibodies, immunogens and compositions related to 5-FU
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
SMT201900296T1 (it) 2011-12-20 2019-07-11 Regeneron Pharma Topi di catena leggera umanizzata
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
WO2013138681A1 (en) 2012-03-16 2013-09-19 Regeneron Pharmaceuticals, Inc. Mice that produce antigen-binding proteins with ph-dependent binding characteristics
US9801362B2 (en) 2012-03-16 2017-10-31 Regeneron Pharmaceuticals, Inc. Non-human animals expressing pH-sensitive immunoglobulin sequences
HUE037659T2 (hu) 2012-03-16 2018-09-28 Regeneron Pharma Hisztidinmódosított könnyûlánc antitestek és genetikailag módosított rágcsálók ennek az elõállítására
SG11201405059XA (en) * 2012-03-28 2014-09-26 Kymab Ltd Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
NZ703689A (en) 2012-06-12 2016-05-27 Regeneron Pharma Humanized non-human animals with restricted immunoglobulin heavy chain loci
RS57582B1 (sr) 2013-02-20 2018-11-30 Regeneron Pharma Nehumane životinje sa modifikovanim sekvencama imunoglobulinskog teškog lanca
SI2958937T1 (sl) * 2013-02-22 2018-12-31 Regeneron Pharmaceuticals, Inc. Miš, ki izraža humanizirani poglavitni histokompatibilnostni kompleks
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
WO2015049517A2 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
EP3068798B1 (en) * 2013-11-12 2020-10-07 OGD2 Pharma Human igg1 derived antibody with pro-apoptotic activity
AU2015230938C1 (en) * 2014-03-21 2021-10-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
SG10201808083VA (en) 2014-03-21 2018-10-30 Regeneron Pharma Vl antigen binding proteins exhibiting distinct binding characteristics
RS60398B1 (sr) * 2014-04-08 2020-07-31 Regeneron Pharma Ne-humane životinje sa humanizovanim fc-gama receptorima
PL3151921T3 (pl) 2014-06-06 2020-02-28 Bristol-Myers Squibb Company Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania
CN104177496B (zh) * 2014-09-02 2015-03-11 安源生物科技(上海)有限公司 人IgG2抗体铰链区修饰体
WO2016054598A2 (en) 2014-10-03 2016-04-07 Massachusetts Institute Of Technology Antibodies that bind ebola glycoprotein and uses thereof
PL3209698T5 (pl) 2014-10-22 2022-04-25 Crescendo Biologics Limited Mysz transgeniczna
JP6805142B2 (ja) 2014-11-21 2020-12-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｄ７３に対する抗体およびその使用
EP3233912B1 (en) 2014-12-19 2021-05-19 Regenesance B.V. Antibodies that bind human c6 and uses thereof
AR103268A1 (es) 2014-12-23 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra tigit
CN107438622A (zh) 2015-03-19 2017-12-05 瑞泽恩制药公司 选择结合抗原的轻链可变区的非人动物
AU2016271111B2 (en) 2015-05-29 2022-04-28 Bristol-Myers Squibb Company Antibodies against OX40 and uses thereof
MX2017016502A (es) 2015-06-29 2018-03-12 Univ Rockefeller Anticuerpos contra cd40 con actividad agonista mejorada.
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
WO2017035252A1 (en) * 2015-08-24 2017-03-02 Trianni, Inc. Enhanced production of immunoglobulins
CN105441455B (zh) * 2015-10-21 2020-08-28 重庆金迈博生物科技有限公司 一种嵌合核酸分子及其在人源化抗体制备中的应用
MX2018006072A (es) 2015-11-19 2018-08-01 Squibb Bristol Myers Co Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos.
EP3384030A4 (en) 2015-12-03 2019-07-03 Trianni, Inc. IMPROVED IMMUNOGLULINIVITY
EP4414484A3 (en) 2016-02-04 2025-01-15 Trianni, Inc. Enhanced production of immunoglobulins
AU2017228470A1 (en) 2016-03-04 2018-08-30 Bristol-Myers Squibb Company Combination therapy with anti-CD73 antibodies
CN116063494A (zh) 2016-03-04 2023-05-05 洛克菲勒大学 具有增强的激动剂活性的cd40的抗体
EP3454864A4 (en) * 2016-04-21 2021-01-13 Abbvie Stemcentrx LLC Novel anti-bmpr1b antibodies and methods of use
US10968279B2 (en) 2016-05-09 2021-04-06 Bristol-Myers Squibb Company TL1A antibodies and uses thereof
SG10202102885UA (en) 2016-05-20 2021-05-28 Regeneron Pharma Methods for breaking immunological tolerance using multiple guide rnas
CN109640644B (zh) 2016-06-03 2021-10-26 瑞泽恩制药公司 表达外源末端脱氧核苷酸转移酶的非人动物
US20190248893A1 (en) 2016-07-14 2019-08-15 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
PL3896091T3 (pl) 2016-08-10 2024-04-29 Legend Biotech Ireland Limited Chimeryczne receptory antygenowe nakierowane na bcma i sposoby ich zastosowania
WO2018044970A1 (en) 2016-08-31 2018-03-08 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
CA3040189A1 (en) 2016-10-13 2018-04-19 Massachusetts Institute Of Technology Antibodies that bind zika virus envelope protein and uses thereof
CN109906030B (zh) * 2016-11-04 2022-03-18 安健基因公司 用于产生仅重链抗体的经基因修饰的非人动物和方法
JP7136790B2 (ja) 2017-02-17 2022-09-13 ブリストル－マイヤーズ スクイブ カンパニー アルファ－シヌクレインに対する抗体およびその使用
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
EP4706687A3 (en) 2017-06-27 2026-07-15 Regeneron Pharmaceuticals, Inc. Tropism-modified recombinant viral particles and uses thereof for the targeted introduction of genetic material into human cells
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
SI3645551T1 (sl) 2017-06-27 2024-06-28 Regeneron Pharmaceuticals, Inc. S tropizmi spremenjeni rekombinantni virusni vektorji in njihova uporaba za tarčni vnos genetskega materiala v človeške celice
GB201710984D0 (en) 2017-07-07 2017-08-23 Kymab Ltd Cells, vertebrates, populations & methods
JP6677277B2 (ja) 2017-07-19 2020-04-08 株式会社デンソー 車両用制御装置及び電源供給回路
AU2018302343B2 (en) 2017-07-21 2020-11-26 Trianni, Inc. Single chain vh and heavy chain antibodies
KR102845020B1 (ko) 2017-12-28 2025-08-12 난징 레전드 바이오테크 씨오., 엘티디. Pd-l1에 대한 항체 및 변이체
SG11202004158QA (en) 2017-12-28 2020-06-29 Nanjing Legend Biotech Co Ltd Single-domain antibodies and variants thereof against tigit
JP7358361B2 (ja) 2018-01-12 2023-10-10 ブリストル－マイヤーズ スクイブ カンパニー Ｔｉｍ３に対する抗体およびその使用
CA3084518A1 (en) 2018-01-15 2019-07-18 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against pd-1
JP7351845B2 (ja) 2018-03-23 2023-09-27 ブリストル－マイヤーズ スクイブ カンパニー Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
EP4534560A3 (en) 2018-03-24 2025-06-11 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
IL277355B2 (en) * 2018-03-26 2025-01-01 Regeneron Pharma Humanized rodents for testing therapeutic agents
AU2019241350B2 (en) 2018-03-30 2025-10-02 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against LAG-3 and uses thereof
WO2019227490A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
JP2021525806A (ja) 2018-06-01 2021-09-27 タユー ファシャ バイオテック メディカル グループ カンパニー， リミテッド 疾患または状態を処置するための組成物およびそれらの使用
CA3102125A1 (en) * 2018-06-13 2019-12-19 Crystal Bioscience Inc. Transgenic chicken that makes antibodies with long cdr-h3s stabilized by multiple disulfide bridges and diversified by gene conversion
WO2019240999A1 (en) * 2018-06-13 2019-12-19 Crystal Bioscience Inc. Camelization of a human variable domain by gene conversion
JP7572861B2 (ja) 2018-06-13 2024-10-24 クリスタル バイオサイエンス インコーポレイテッド 遺伝子変換による自律型重鎖可変ドメインの改変による抗体の産生
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
GB2576914A (en) 2018-09-06 2020-03-11 Kymab Ltd Antigen-binding molecules comprising unpaired variable domains produced in mammals
WO2020052543A1 (en) 2018-09-10 2020-03-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against cd33 and constructs thereof
MX2021005708A (es) 2018-11-16 2021-09-21 Bristol Myers Squibb Co Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos.
CN118894938A (zh) 2019-01-22 2024-11-05 百时美施贵宝公司 抗IL-7Rα亚基的抗体及其用途
CN113795511B (zh) 2019-01-23 2024-07-23 大有华夏生物医药集团有限公司 抗pd-l1双抗体及其用途
AU2020283537A1 (en) 2019-05-24 2021-12-16 Regeneron Pharmaceuticals, Inc. Modified viral particles and uses thereof
WO2021113297A1 (en) 2019-12-02 2021-06-10 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
CN110818795B (zh) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法
CN115298322A (zh) * 2020-01-17 2022-11-04 贝克顿迪金森公司 用于单细胞分泌组学的方法和组合物
WO2021154993A1 (en) * 2020-01-28 2021-08-05 University Of Southern California Genome engineering the human immunoglobulin locus to express recombinant binding domain molecules
JP7715722B2 (ja) 2020-02-28 2025-07-30 上海復宏漢霖生物技術股▲フン▼有限公司 抗ｃｄ１３７コンストラクト及びその使用
KR20220145859A (ko) 2020-02-28 2022-10-31 상하이 헨리우스 바이오테크, 인크. 항cd137 작제물, 다중 특이적 항체 및 그 용도
CN111333719B (zh) * 2020-03-16 2021-10-01 西南大学 抗hpv16e7蛋白单抗69a6、杂交瘤细胞及其制备方法和应用
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
WO2021247769A1 (en) 2020-06-02 2021-12-09 Dynamicure Biotechnology Llc Anti-cd93 constructs and uses thereof
CN116529260A (zh) 2020-06-02 2023-08-01 当康生物技术有限责任公司 抗cd93构建体及其用途
WO2021257679A1 (en) 2020-06-17 2021-12-23 Janssen Biotech, Inc. Materials and methods for the manufacture of pluripotent stem cells
AU2021297540A1 (en) 2020-06-24 2023-02-02 Prothena Biosciences Limited Antibodies recognizing sortilin
CN116193985A (zh) * 2020-07-13 2023-05-30 加拿大商木曾路生物科技公司 表达重链抗体的转基因动物
CA3186065A1 (en) 2020-07-16 2022-01-20 Xiaohu FAN Cd19 binding molecules and uses thereof
JP7846667B2 (ja) 2020-07-16 2026-04-15 レジェンド バイオテック アイルランド リミテッド Ｃｄ２０結合分子及びその使用
IL300121A (en) 2020-07-29 2023-03-01 Dynamicure Biotechnology Llc Anti-cd93 constructs and uses thereof
IL300505A (en) 2020-08-10 2023-04-01 Janssen Biotech Inc Materials and methods for the production of biologically engineered virus-specific lymphocytes
CN114134144A (zh) * 2020-09-04 2022-03-04 北京仁源欣生生物科技有限公司 一种非人哺乳动物或其子代的制备方法及其应用
US20220090060A1 (en) 2020-09-11 2022-03-24 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
PH12023550779A1 (en) 2020-09-28 2023-11-20 Angitia Biomedicines Ltd Anti-sclerostin constructs and uses thereof
CN116723861A (zh) 2020-12-02 2023-09-08 上海复宏汉霖生物技术股份有限公司 抗GARP/TGFβ抗体及使用方法
JP7822400B2 (ja) * 2020-12-09 2026-03-02 トリアンニ，インコーポレーテッド 重鎖のみ抗体
WO2022130023A1 (en) 2020-12-14 2022-06-23 University Health Network Immunoglobulin light chain antibodies and uses thereof
EP4262373A1 (en) 2020-12-16 2023-10-25 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
MX2023007401A (es) 2020-12-23 2023-07-06 Regeneron Pharma Acidos nucleicos que codifican anticuerpos modificados por anclaje y usos de los mismos.
BR112023016713A2 (pt) 2021-02-19 2023-10-31 Seoul Nat Univ R&Db Foundation Anticorpo ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucleico, métodos para produzir um anticorpo ou um fragmento de ligação ao antígeno do mesmo e para detectar agrupamento de diferenciação 47 ou determinar uma quantidade de agrupamento de diferenciação 47 em uma amostra, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo
CN116917322A (zh) 2021-02-19 2023-10-20 沙裴隆有限公司 针对pd-l1及cd47的双特异性单域抗体及其用途
BR112023016706A2 (pt) 2021-02-19 2023-10-31 Seoul Nat Univ R&Db Foundation Anticorpo ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucleico, métodos para produzir um anticorpo ou um fragmento de ligação ao antígeno do mesmo e para detectar agrupamento de diferenciação 47 ou determinar uma quantidade de agrupamento de diferenciação 47 em uma amostra, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo
JP2024507958A (ja) 2021-02-26 2024-02-21 ナンジン レジェンド バイオテック カンパニー，リミテッド 外因的に導入されたサイトカインを発現する操作された免疫エフェクター細胞
CN117715933A (zh) 2021-03-05 2024-03-15 当康生物技术有限责任公司 抗vista的构建体及其用途
WO2022204724A1 (en) 2021-03-25 2022-09-29 Dynamicure Biotechnology Llc Anti-igfbp7 constructs and uses thereof
JP7555296B2 (ja) * 2021-03-31 2024-09-24 太平洋セメント株式会社 二酸化炭素の固定化方法
EP4333614A4 (en) * 2021-05-05 2025-04-09 Leveragen, Inc. MANIPULATED NON-HUMAN ANIMALS TO PRODUCE ANTIBODIES
CN117651486A (zh) * 2021-05-05 2024-03-05 利威瑞健股份有限公司 用于生产抗体的工程改造的非人动物
EP4355785A1 (en) 2021-06-17 2024-04-24 Amberstone Biosciences, Inc. Anti-cd3 constructs and uses thereof
MX2023015461A (es) * 2021-06-17 2024-01-18 Fapon Biotech Inc Inmunoglobulina quimerica.
US20230174651A1 (en) 2021-06-23 2023-06-08 Janssen Biotech, Inc. Materials and methods for hinge regions in functional exogenous receptors
US20230062964A1 (en) * 2021-08-30 2023-03-02 New York University Modified mice that produce heavy chain only antibodies
MX2024005314A (es) 2021-11-04 2024-05-17 Regeneron Pharma Particulas virales redirigidas a musculo esqueletico.
AU2022411573A1 (en) 2021-12-17 2024-06-27 Shanghai Henlius Biologics Co., Ltd. Anti-ox40 antibodies and methods of use
CN118488965A (zh) 2021-12-17 2024-08-13 上海复宏汉霖生物技术股份有限公司 抗ox40抗体、多特异性抗体及其使用方法
US20250154237A1 (en) * 2022-02-24 2025-05-15 A & G Pharmaceutical, Inc. Fully human monoclonal antibodies against human progranulin
KR20240163119A (ko) 2022-03-25 2024-11-18 상하이 헨리우스 바이오테크, 인크. 항-msln 항체 및 사용 방법
AU2023269134A1 (en) 2022-05-09 2024-12-12 Regeneron Pharmaceuticals, Inc. Vectors and methods for in vivo antibody production
CN119907674A (zh) 2022-07-22 2025-04-29 詹森生物科技公司 遗传指令向效应免疫细胞的增强转移
MA71631A (fr) 2022-07-29 2025-05-30 Regeneron Pharmaceuticals, Inc. Particules virales reciblées vers le récepteur 1 de transferrine
US20260078185A1 (en) 2022-09-07 2026-03-19 Dynamicure Biotechnology Llc Anti-vista constructs and uses thereof
IL319494A (en) * 2022-09-16 2025-05-01 Biocytogen Pharmaceuticals Beijing Co Ltd Genetically modified non-human animals and methods for producing heavy chain antibodies
WO2024102454A1 (en) * 2022-11-09 2024-05-16 Leveragen, Inc. Engineered non-human animals
US20260217828A1 (en) 2023-01-31 2026-07-30 University Of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
CN121039163A (zh) 2023-05-02 2025-11-28 瑞泽恩制药公司 抗人m-钙粘蛋白（cdh15）抗体、缀合物及其用于将遗传有效负载递送至肌肉细胞的用途
WO2025034806A1 (en) 2023-08-08 2025-02-13 Wisconsin Alumni Research Foundation Single-domain antibodies and variants thereof against fibroblast activation protein
EP4512243A1 (en) 2023-08-21 2025-02-26 Kymab Limited Binding molecules
CN122003435A (zh) 2023-09-03 2026-05-08 科越医药(美国)有限责任公司 包含抗因子d部分的多特异性构建体
WO2025064738A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Dntt 250-258 off-target peptides and uses thereof
WO2025064761A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Kras10-18 g12d off-target peptides and uses thereof
AU2025207849A1 (en) 2024-01-11 2026-07-16 Regeneron Pharmaceuticals, Inc. Viral particles retargeted to nervous system tissues
WO2025178959A1 (en) 2024-02-20 2025-08-28 University Of Georgia Research Foundation, Inc. Single-domain antibodies and variants thereof against tab1
US20250361320A1 (en) 2024-02-27 2025-11-27 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
WO2026006724A1 (en) 2024-06-28 2026-01-02 Regeneron Pharmaceuticals, Inc. Prame off-target peptides and uses thereof
WO2026006734A1 (en) 2024-06-28 2026-01-02 Regeneron Pharmaceuticals, Inc. Off-target peptide-mhc complex conformation modeling systems and methods for antigen-recognition molecule development
WO2026025058A1 (en) 2024-07-25 2026-01-29 Regeneron Pharmaceuticals, Inc. Aav viral particles retargeted to egfr-expressing cancer cells
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof
US20260123608A1 (en) 2024-08-06 2026-05-07 Regeneron Pharmaceuticals, Inc. Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof
WO2026086785A1 (en) 2024-10-21 2026-04-30 Shenzhen Wondercel Biotechnology Limited Eukaryotic cells expressing exogenous inosine monophosphate dehydrogenase comprising chimeric antigen receptor binding to gucy2c
WO2026096736A1 (en) 2024-10-31 2026-05-07 Regeneron Pharmaceuticals, Inc. Rodents expressing humanized polymeric immunoglobulin receptor
US20260144884A1 (en) 2024-11-22 2026-05-28 Bristol-Myers Squibb Company Anti-lrrc15 antibody drug conjugates
US20260144885A1 (en) 2024-11-22 2026-05-28 Bristol-Myers Squibb Company Anti-lrrc15 antibodies and uses thereof

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US7041871B1 (en) * 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
AU781922B2 (en) * 1991-12-17 2005-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6080910A (en) 1997-02-20 2000-06-27 Case Western Reserve University Transgenic knockout animals lacking IgG3
US7083950B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
CN101498731A (zh) * 2000-05-18 2009-08-05 日本烟草产业株式会社 抗协同刺激信号转导分子ailim的人单克隆抗体及其药物用途
IL154751A0 (en) 2000-08-03 2003-10-31 Humanized antibodies, recombination vectors, transgenic vectors and methods for the preparation of humanized antibodies from transgenic animals
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7235643B2 (en) 2000-11-07 2007-06-26 Morphotek, Inc. Antibodies and methods for generating genetically altered antibodies with high affinity
CN101016543A (zh) * 2000-11-17 2007-08-15 罗切斯特大学 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的多核苷酸的方法
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
GB0110029D0 (en) * 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
JP4303105B2 (ja) 2001-06-28 2009-07-29 ドマンティス リミテッド 二重特異性リガンドとその利用
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US7393648B2 (en) 2001-12-03 2008-07-01 Alexion Pharmaceuticals, Inc. Hybrid antibodies
US7241733B2 (en) 2002-06-28 2007-07-10 Centocor, Inc. Mammalian EPO mimetic CH1 deleted mimetibodies, compositions, methods and uses
CN1678634A (zh) 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
FR2861255B1 (fr) * 2003-10-24 2006-02-17 Centre Nat Rech Scient Mammifere non-humain transgenique pour la region constante de la chaine lourde des immunoglobulines humaines de classe a et ses applications.
JP4906094B2 (ja) 2004-01-16 2012-03-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド レセプターを活性化し得る融合ポリペプチド
US20060024302A1 (en) * 2004-03-05 2006-02-02 Ludwig Institute For Cancer Research Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same
EP1776383B1 (en) 2004-07-22 2014-08-20 Erasmus University Medical Center Rotterdam Binding molecules
EP1802193B1 (en) 2004-10-19 2014-04-30 Regeneron Pharmaceuticals, Inc. Method for generating a mouse homozygous for a genetic modification
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
EP1874817A2 (en) 2005-04-29 2008-01-09 Innate Pharma Transgenic animals and methods of making recombinant antibodies
KR101866623B1 (ko) * 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 １가 항체 및 그의 제조 방법
GB0618345D0 (en) 2006-09-18 2006-10-25 Univ Erasmus Binding molecules
TWI404727B (zh) 2006-01-25 2013-08-11 荷蘭鹿特丹Ｅｒａｓｍｕｓ大學醫學中心 對偶基因排除
DE602007009954D1 (de) * 2006-03-22 2010-12-02 Viral Logic Systems Technology Verfahren zur identifizierung von polypeptid-targets
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
GB0706628D0 (en) 2007-04-04 2007-05-16 Univ Erasmus Germ-line manipulation 1
KR101703299B1 (ko) 2007-06-01 2017-02-06 오픈 모노클로날 테크놀로지, 인코포레이티드 내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물
WO2008151319A2 (en) 2007-06-08 2008-12-11 Dow Global Technologies Inc. Expression of soluble antibody fragment by truncation of ch1 domain
WO2009013620A2 (en) 2007-06-11 2009-01-29 Erasmus University Medical Center Rotterdam Homologous recombination
AU2008295248A1 (en) 2007-09-07 2009-03-12 Symphogen A/S Methods for recombinant manufacturing of anti-RSV antibodies
EP2262898B1 (en) 2008-03-07 2018-01-24 Regeneron Pharmaceuticals, Inc. Es cell-derived mice from diploid host embryo injection
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
WO2011072204A1 (en) * 2009-12-10 2011-06-16 Regeneron Pharmaceuticals, Inc. Mice that make heavy chain antibodies
JP6023667B2 (ja) * 2013-06-26 2016-11-09 矢崎総業株式会社 コネクタ
JP5602929B1 (ja) * 2013-11-08 2014-10-08 株式会社小松製作所 モータグレーダのリッパー装置およびこれを備えたモータグレーダ

Also Published As

Publication number Publication date
CA2782936C (en) 2019-06-18
SG181477A1 (en) 2012-07-30
RS58709B1 (sr) 2019-06-28
KR101553244B1 (ko) 2015-09-15
PT2954779T (pt) 2019-05-29
US20150197557A1 (en) 2015-07-16
CA2782936A1 (en) 2011-06-16
US20150197556A1 (en) 2015-07-16
DK2509409T3 (en) 2016-11-14
JP2015077147A (ja) 2015-04-23
JP2017140058A (ja) 2017-08-17
US12543713B2 (en) 2026-02-10
IL237818A (en) 2016-08-31
ES2595376T3 (es) 2016-12-29
EP2509409A1 (en) 2012-10-17
MY172472A (en) 2019-11-26
HK1220865A1 (en) 2017-05-19
HK1177100A1 (en) 2013-08-16
RU2603102C2 (ru) 2016-11-20
ES2724975T3 (es) 2019-09-18
US11234419B2 (en) 2022-02-01
US8754287B2 (en) 2014-06-17
US20140289876A1 (en) 2014-09-25
DK2954779T3 (da) 2019-05-13
CN102711449A (zh) 2012-10-03
CY1121608T1 (el) 2020-05-29
EP2954779A1 (en) 2015-12-16
MY173363A (en) 2020-01-21
JP6615830B2 (ja) 2019-12-04
SMT201900251T1 (it) 2019-07-11
US20150197554A1 (en) 2015-07-16
EP2954779B1 (en) 2019-02-06
JP5909449B2 (ja) 2016-04-26
KR101430514B1 (ko) 2014-08-19
US20220201993A1 (en) 2022-06-30
US20110145937A1 (en) 2011-06-16
HUE043556T2 (hu) 2019-09-30
EP3504964A1 (en) 2019-07-03
HRP20190820T1 (hr) 2019-09-20
IL257822A (en) 2018-04-30
CN110079550A (zh) 2019-08-02
JP2015133991A (ja) 2015-07-27
CY1118163T1 (el) 2017-06-28
JP2019141095A (ja) 2019-08-29
KR20130055556A (ko) 2013-05-28
EP2509409B1 (en) 2016-07-27
JP6293702B2 (ja) 2018-03-14
AU2010328046A1 (en) 2012-07-12
JP2013513388A (ja) 2013-04-22
SI2954779T1 (sl) 2019-06-28
LT2509409T (lt) 2016-12-12
RU2012128856A (ru) 2014-01-20
SI2509409T1 (sl) 2016-12-30
IL237819A (en) 2017-03-30
US9888675B2 (en) 2018-02-13
US20150197553A1 (en) 2015-07-16
JP6271450B2 (ja) 2018-01-31
US20150197555A1 (en) 2015-07-16
SG10201408181PA (en) 2015-01-29
CN102711449B (zh) 2015-01-07
PL2954779T3 (pl) 2019-07-31
KR20140024970A (ko) 2014-03-03
US20150196015A1 (en) 2015-07-16
IL257822B (en) 2020-01-30
LT2954779T (lt) 2019-05-27
AU2010328046B2 (en) 2014-07-31
IL220150A0 (en) 2012-07-31
PT2509409T (pt) 2016-09-29
HUE030208T2 (en) 2017-04-28
WO2011072204A1 (en) 2011-06-16
CN104131035A (zh) 2014-11-05
PL2509409T3 (pl) 2017-02-28
TR201906488T4 (tr) 2019-05-21

Similar Documents

Publication Publication Date Title
US12543713B2 (en) Mice that make heavy chain antibodies
JP2013513388A5 (enExample)
AU2017261477C1 (en) Mice that make heavy chain antibodies
HK40010699A (en) Mice that make heavy chain antibodies
HK1220865B (en) Mice that make heavy chain antibodies
HK1177100B (en) Mice that make heavy chain antibodies

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 06 AUG 2014 .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 06 AUG 2014

FGA Letters patent sealed or granted (standard patent)
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ MACDONALD, LYNN; STEVENS, SEAN AND MURPHY, ANDREW J.

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 15 SEP 2017

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 15 SEP 2017